A Study of LY2409021 Formulations in Healthy Participants

Stopped early · Phase 1

Conditions studied: Healthy

In brief

The purpose of this study is to measure how much of the new LY2409021 tablet formulations get into the blood stream and how long it takes the body to get rid of them, compared to the current LY2409021 capsule formulation. In addition, the safety and tolerability of both the new and current formulations will be evaluated. Information about any side effects that may occur will also be collected. The study has two parts. Each participant may enroll in one part only. The study will last up to 8 weeks for each participant. Screening is required prior to the start of the study.

Key facts

Study ID: NCT02385084
Run by: Eli Lilly and Company
People needed: 18
Starts: 2015-03-01
Expected to finish: 2015-05-01
Last updated by the study team: 2018-10-29

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Overtly healthy males or surgically sterile or postmenopausal females, as determined by medical history and physical examination
Have a body mass index (BMI) of 18.0 to 32.0 kilogram per square meter (kg/m\^2)
Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator

You may not qualify if…

Have known allergies to LY2409021, related compounds or any components of the formulation, or history of significant atopy
Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
Have known or ongoing psychiatric disorders

Where it is running

Covance CRU, Inc — Daytona Beach, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.